Insights

Why don’t we trust people’s lived-experience of fatigue?

Fatigue is the sort of subjective phenomenological experience that has plagued philosophers and neuroscientists for centuries. For those with lived experience, fatigue can be debilitating, and patients can be left feeling ignored and maligned. Despite over 17 million people across Europe1, reporting symptoms of Long Covid, with fatigue being the most common symptom, there is …

Why don’t we trust people’s lived-experience of fatigue? Read More »

Speech based biomarkers for monitoring progressive changes in Alzheimer’s disease

A speech based composite which tracks change in AD over time was recently developed and piloted through a collaboration between Winterlight Labs and Genentech.

Speech is a rich source of clinical information when assessing and monitoring Alzheimer’s Disease. Natural language processing technologies, like those developed by Winterlight Labs, can objectively quantify speech and enable its use as a novel endpoint in drug development.

The next generation of treatments for Alzheimer’s Disease in clinical trials

The latest advances in the treatment of Alzheimer’s disease and how Cambridge Cognition are designing and implementing empirically validated and clinically-relevant cognitive tasks to help develop the next generation of Alzheimer’s disease treatments. 

There are presently over 140 drugs being explored as possible treatments for Alzheimer’s Disease (AD) in clinical trials. Of these, nearly 80% are intended to slow the progression of AD. Historically, cholinesterase inhibitor drugs such as galantamine, rivastigmine and donepezil have been approved for treatment of AD. These drugs have been shown to mitigate symptoms of AD, such as memory loss, however they are unable to treat the underlying neurobiological cause of the condition. As such, these drugs do not slow AD progression and are not considered a long-term solution in the battle to end the most common form of neurodegenerative disease.

Highlights from AAIC 2023

The headline from this year’s AAIC in Amsterdam is undoubtedly the announcement of the results of TRAILBLAZER-ALZ-2, a phase 3 trial of Eli Lilly’s new drug Donanemab with 1,800 participants. Donanemab is an antibody-based drug that works by breaking down already-formed amyloid plaques that build up in Alzheimer’s disease (AD), rather than interfering with their production.

Using a multidisciplinary approach to characterise the neurobiology of addiction

Insights Back to resource centre 6 October 2022 Understanding the effect of ashwagandha root extract on stress, sleep and cognition We caught up with Shefali Thanawala from Nutriventia Ltd who told us how CANTAB™ helped them to investigate the effects of Ashwagandha root extract on memory and focus in healthy, stressed adults. About Nutriventia, Ltd.Nutriventia Limited is the dietary supplements

Pictures of Ed and Yasmin

Improvements and personalisation of research and treatment in schizophrenia and psychosis-related disorders; observations from Schizophrenia International Research Society (SIRS) 2023 conference.

Insights Back to resource centre 31 May 2023 Improvements and personalisation of research and treatment in schizophrenia and psychosis-related disorders; observations from Schizophrenia International Research Society (SIRS) 2023 conference. Earlier this month we had the pleasure of attending the Schizophrenia International Research Society (SIRS) conference in Toronto, Canada. We were delighted to present our recent findings from our meta-analysis comparing

Team members from University of Sinagpore

Measuring cognition in areas outside of the Central Nervous System

Insights Back to resource centre 24 April 2023 Measuring cognition in areas outside of the Central Nervous System CANTAB® cognitive assessments are often used to measure cognition in disorders of the Central Nervous System, but did you know that they are also used in research that don’t involve the CNS? Here, two research teams explain how CANTAB is supporting their

Speech phenotypes in cognitively health participants at risk of developing Alzheimer's disease

Speech phenotypes in cognitively healthy participants at risk of developing Alzheimer’s disease

Insights Back to resource centre 4 April 2023 Speech phenotypes in cognitively healthy participants at risk of developing Alzheimer’s disease This poster was presented at AD/PD in March 2023 and represents collaborative work between Winterlight Labs and Novartis. Poster SummaryChanges to speech patterns have been identified as early signs of Alzheimer’s Disease (AD) and have been shown to progress with

Picture of Anders Aasheim

Using CANTAB to understand more about depth of anaesthesia and post-operative cognitive dysfunction

Insights Back to resource centre 21 March 2023 Using CANTAB to understand more about depth of anaesthesia and post-operative cognitive dysfunction We caught up with Anders Aasheim from Oslo University Hospital who told us more about his team’s research in understanding the effect of anaesthesia on cognitive function. My name is Anders Aasheim, and I am a nurse anaesthetist and

My career story: Naomi McPartlan, Clinical Project Coordinator

Insights Back to resource centre 15 March 2023 My career story: Naomi McPartlan, Clinical Project Coordinator We chatted to Naomi about her role, her career to date and what advice she has for anyone thinking of a career in clinical trials and health technology.When did you join Cambridge Cognition and what is your role?I started at the beginning of July 2022 as

Scroll to Top